# Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

> **NCT06354660** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 537 (actual)

## Conditions studied

- Diabetes Type 2

## Interventions

- **DRUG:** Retatrutide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06354660
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-10
- **Primary completion:** 2026-01-22
- **Final completion:** 2026-02-20
- **Target enrollment:** 537 (ACTUAL)
- **Last updated:** 2026-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06354660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06354660, "Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06354660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*